BRAF and neoplasm: NCT02858921 is a phase II trial designed to determine the optimal combination of drugs (dabrafenib, trametinib, and/or pembrolizumab) to reduce tumor size prior to surgery for patients with BRAF V600-mutated, resectable stage IIIB/C melanoma [38].